These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9041667)

  • 1. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults.
    Krah DL; Cho I; Schofield T; Ellis RW
    Vaccine; 1997 Jan; 15(1):61-4. PubMed ID: 9041667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
    Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
    Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection.
    Li S; Chan IS; Matthews H; Heyse JF; Chan CY; Kuter BJ; Kaplan KM; Vessey SJ; Sadoff JC
    Pediatr Infect Dis J; 2002 Apr; 21(4):337-42. PubMed ID: 12075766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.
    Hammond O; Wang Y; Green T; Antonello J; Kuhn R; Motley C; Stump P; Rich B; Chirmule N; Marchese RD
    J Med Virol; 2006 Dec; 78(12):1679-87. PubMed ID: 17063506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults.
    Paradis EM; Tikhonov O; Cao X; Kharit SM; Fokin A; Platt HL; Banniettis N
    Hum Vaccin Immunother; 2021 Nov; 17(11):4177-4182. PubMed ID: 34473594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of Bio Pox™, a live varicella vaccine (Oka strain) in Indian children: A comparative multicentric, randomized phase II/III clinical trial.
    Dubey AP; Faridi MMA; Mitra M; Kaur IR; Dabas A; Choudhury J; Mukherjee M; Mishra D
    Hum Vaccin Immunother; 2017 Sep; 13(9):2032-2037. PubMed ID: 28509605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy infants, children, and adolescents.
    Paradis EM; Tikhonov O; Cao X; Kharit SM; Fokin A; Platt HL; Wittke F; Jotterand V
    Hum Vaccin Immunother; 2021 Nov; 17(11):4183-4189. PubMed ID: 34702124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization.
    Haumont M; Jurdan M; Kangro H; Jacquet A; Massaer M; Deleersnyder V; Garcia L; Bosseloir A; Bruck C; Bollen A; Jacobs P
    J Med Virol; 1997 Sep; 53(1):63-8. PubMed ID: 9298734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
    Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children.
    Ngai AL; Staehle BO; Kuter BJ; Cyanovich NM; Cho I; Matthews H; Keller P; Arvin AM; Watson B; White CJ
    Pediatr Infect Dis J; 1996 Jan; 15(1):49-54. PubMed ID: 8684876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®.
    Reisinger KS; Richardson E; Malacaman EA; Levin MJ; Gardner JL; Wang W; Stek JE; Kuter B
    Vaccine; 2019 Sep; 37(38):5788-5795. PubMed ID: 30146405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody assays suitable for assessing immune responses to live varicella vaccine.
    Provost PJ; Krah DL; Kuter BJ; Morton DH; Schofield TL; Wasmuth EH; White CJ; Miller WJ; Ellis RW
    Vaccine; 1991 Feb; 9(2):111-6. PubMed ID: 1647574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine.
    Watson B; Gupta R; Randall T; Starr S
    J Infect Dis; 1994 Jan; 169(1):197-9. PubMed ID: 8277182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response after varicella vaccination in children treated with budesonide inhalation suspension or non-steroidal conventional asthma therapy.
    Murphy K; Ververeli K; Harvey BM; Duke AL; Chapas-Crilly J; Uryniak T; Lyzell E; Mezzanotte W
    Int J Clin Pract; 2006 Dec; 60(12):1548-57. PubMed ID: 17109664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seropositivity of Varicella zoster virus in vaccinated Korean children and MAV vaccine group.
    Choi UY; Huh DH; Kim JH; Kang JH
    Hum Vaccin Immunother; 2016 Oct; 12(10):2560-2564. PubMed ID: 27484734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of single dose live attenuated varicella vaccine (VR 795 Oka strain) in healthy Indian children: a randomized controlled study.
    Mitra M; Faridi M; Ghosh A; Shah N; Shah R; Chaterjee S; Narang M; Bhattacharya N; Bhat G; Choudhury H; Kadhe G; Mane A; Roy S
    Hum Vaccin Immunother; 2015; 11(2):443-9. PubMed ID: 25692656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children.
    Lau YL; Vessey SJ; Chan IS; Lee TL; Huang LM; Lee CY; Lin TY; Lee BW; Kwan K; Kasim SM; Chan CY; Kaplan KM; Distefano DJ; Harmon AL; Golie A; Hartzel J; Xu J; Li S; Matthews H; Sadoff JC; Shaw A
    Vaccine; 2002 Jul; 20(23-24):2942-9. PubMed ID: 12126906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A study for the necessity of virus titer of varicella vaccine presently used].
    Ozaki T; Nishimura N; Gotoh K; Funahashi K
    Kansenshogaku Zasshi; 2012 Nov; 86(6):749-54. PubMed ID: 23367850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety profile of varicella vaccine: a 10-year review.
    Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
    J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group.
    Kuter BJ; Ngai A; Patterson CM; Staehle BO; Cho I; Matthews H; Provost PJ; White CJ
    Vaccine; 1995 Aug; 13(11):967-72. PubMed ID: 8525689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.